Brian Hawkins is an expert on barriers of the central nervous system (CNS) with more than 15 years of experience in both in vivo and in vitro model systems. His work at RTI involves developing in vitro model systems for evaluating CNS drug disposition, efficacy, and toxicity.
Before joining RTI in July 2013, Dr. Hawkins was a research faculty member at the University of Washington School of Medicine and a postdoctoral fellow at the National Institute of Environmental Health Sciences.
He has studied the effects of nicotine and diabetes on blood-brain barrier function, molecular regulation of drug efflux transporters, and cell-matrix interactions in the neurovascular unit. He has contributed to numerous projects funded by both the National Institutes of Health and the pharmaceutical industry.
Dr. Hawkins is a co-author of more than 20 peer-reviewed publications, including papers in The Journal of Neuroscience, Proceedings of the National Academy of Sciences, and The New England Journal of Medicine, as well as several book chapters. He has presented at many national and international meetings, such as the Society for Neuroscience, Cerebral Vascular Biology (CVB), and the Gordon Research Conference on Barriers of the CNS. He is a founding member of the International Brain Barriers Society.